Bausch Health Cos., Inc.(Toronto Stock Exchange : BHC)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Other
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PTLA | Portola Pharmaceuticals, Inc. | 0.56% | 17.95 | 6.5% | $165.07m | |
| HZNP | Horizon Therapeutics Plc | 4.06% | 50.73 | 6.5% | $146.36m | |
| CTLT | Catalent, Inc. | 0.81% | 77.52 | 2.3% | $138.66m | |
| MYOK | MyoKardia, Inc. | 2.14% | 102.29 | 1.8% | $130.35m | |
| BHC | Bausch Health Cos., Inc. | -0.75% | 18.44 | 0.0% | $119.26m | |
| VRX | Valeant Pharmaceuticals International, Inc. | -0.75% | 18.44 | 14.1% | $108.50m | |
| UTHR | United Therapeutics Corp. | 2.57% | 117.95 | 14.3% | $75.18m | |
| JAZZ | Jazz Pharmaceuticals Plc | 0.45% | 119.32 | 2.4% | $60.64m | |
| ICPT | Intercept Pharmaceuticals, Inc. | -0.66% | 72.26 | 16.8% | $59.67m | |
| AMRN | Amarin Corp. Plc | 0.44% | 6.86 | 1.6% | $57.99m | |
| GWPH | GW Pharmaceuticals Plc | -2.16% | 122.75 | 6.2% | $55.98m | |
| ARGX | argenx SE | 3.60% | 219.30 | 0.0% | $52.90m | |
| AXSM | Axsome Therapeutics, Inc. | 0.60% | 76.98 | 1.9% | $50.67m | |
| PRGO | Perrigo Co. Plc | -0.42% | 54.80 | 6.8% | $45.78m | |
| ICLR | ICON plc | 1.72% | 168.45 | 4.3% | $44.44m |
Company Profile
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.